Red Yeast Rice
Monascus purpureus
A natural statin source that lowers LDL cholesterol, but with statin-grade risks and wildly inconsistent dosing.
Moderate evidence
🫀Heart & Metabolic
Evidence tier
Moderate
Research weight
Citations
12 verified / 12
Classification
Heart & Metabolic
❝
What the evidence says. Graded moderate because it reliably lowers LDL cholesterol in RCTs — it contains a real statin (lovastatin) — but unpredictable dosing, contamination risk and statin-grade harms cap confidence. It is effective, not safe to self-prescribe. (Moderate evidence: Several controlled trials; effects real but modest or context-dependent.)
⚠
Health warning. Its active compound, monacolin K, is chemically identical to the prescription statin lovastatin, so red yeast rice carries statin-grade risks — muscle injury (rarely rhabdomyolysis) and liver injury — yet the dose is unregulated and varies wildly between products, some of which are contaminated with the kidney-toxic mould toxin citrinin. The EU could not establish any safe intake. Treat it like a prescription statin: only under medical supervision, never alongside one.
What is Red Yeast Rice?
Red Yeast Rice (Monascus purpureus) is a heart and metabolic supplement used for lowers ldl ('bad') cholesterol, with pooled reductions of roughly 28-36 mg/dl in meta-analyses of randomized trials. NutriDex grades the human evidence as Moderate. Red yeast rice is rice fermented with the mold Monascus purpureus, which produces monacolin K, a molecule chemically identical to the prescription statin lovastatin. Through this statin, it reliably lowers LDL cholesterol; meta-analyses of randomized trials report pooled LDL reductions of roughly 28-36 mg/dL, comparable to low-dose statins. The central problem is consistency and safety: independent testing shows monacolin content varies dramatically between products, some contain almost none while others rival a prescription dose, and some lots are contaminated with the nephrotoxic mycotoxin citrinin. Because the active compound is a statin, red yeast rice carries the same potential adverse effects, including muscle injury (myopathy, rarely rhabdomyolysis) and liver injury, although meta-analyses of trials and pharmacovigilance data suggest the absolute risk at low doses is low. The European Food Safety Authority concluded in 2018 and reaffirmed in 2025 that no safe monacolin intake level could be established, even as low as 3 mg/day, leading the EU to restrict these products. In short, it works because it is a statin, and it should be treated with the same caution as one.
Purported Benefits
✓Lowers LDL ('bad') cholesterol, with pooled reductions of roughly 28-36 mg/dL in meta-analyses of randomized trials
✓Modestly reduces total cholesterol and triglycerides
✓Can offer a cholesterol-lowering option for some people who cannot tolerate prescription statins, though it carries the same risks
✓May produce small reductions in blood pressure in mild dyslipidemia in some trials
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| LDL cholesterol loweringMultiple RCT meta-analyses show LDL down ~28-36 mg/dL, near statin-equivalent; but monacolin content varies wildly by product. | Strong | ↑ benefit · large | 5 |
| Total cholesterol & triglyceridesTrials show modest reductions in total cholesterol and triglycerides alongside the LDL effect. | Moderate | ↑ benefit · moderate | 2 |
| Major cardiovascular events / mortalityRests largely on one purified-extract (Xuezhikang) post-MI RCT cutting events ~45%; not generalizable to variable OTC products. | Moderate | ↑ benefit · large | 1 |
| Statin-intolerant patients (tolerability)Expert panel deems it an option for statin-intolerant patients, but it IS a statin and carries the same myopathy/liver risks. | Moderate | ↑ benefit · moderate | 1 |
| Muscle/liver safetyTrial/pharmacovigilance data suggest low harm at low doses, but EFSA finds no safe monacolin level; citrinin contamination a concern. | Mixed | ↔ mixed | 4 |
| Blood pressureEntry notes small BP reductions in some mild-dyslipidemia trials; evidence is thin and secondary. | Preliminary | ↑ benefit · small | 1 |
Dosing & Compounds
Typical Dose
Studied at 200-4,800 mg/day of RYR powder, standardized to monacolin K. The EU caps supplements at under 3 mg total monacolins/day; older U.S. products often supplied ~5-10 mg/day. Monacolin content varies enormously between (and within) products, so the effective dose is unpredictable.
Active Compounds
Safety & Cautions
Because monacolin K IS a statin (lovastatin), red yeast rice carries statin-class risks and should be treated like a prescription drug. Do NOT use if pregnant, breastfeeding, or trying to conceive; if you have active liver disease or unexplained elevated liver enzymes; or if you have a history of statin-related muscle injury. Stop and seek care for unexplained muscle pain, tenderness, weakness, or dark urine (possible myopathy/rhabdomyolysis) and watch for signs of liver injury (fatigue, jaundice, right-upper-abdominal pain). Avoid combining with prescription statins or with drugs that raise statin levels, including strong CYP3A4 inhibitors (certain azole antifungals, macrolide antibiotics, HIV protease inhibitors), fibrates, cyclosporine, and large amounts of grapefruit juice; it may also interact with warfarin and other medications. Product quality is a major hazard: monacolin content varies greatly between brands and some products are contaminated with citrinin, a nephrotoxic mycotoxin. EFSA could not establish any safe dose and the EU restricts these products; the U.S. FDA considers products with substantial lovastatin to be unapproved drugs. Anyone with cardiovascular risk should manage cholesterol under a clinician with monitoring, not self-treat. Educational only — always check with your doctor or pharmacist before combining Red Yeast Rice with any medicine.
Red Yeast Rice drug interactions
Known or theoretical interactions between Red Yeast Rice and common medications — educational, not exhaustive. Always check with your doctor or pharmacist before combining Red Yeast Rice with any medicine.
Avoid
Statins
Contains monacolin K (= lovastatin); stacking with a statin duplicates dosing — myopathy risk.
Monacolin K is chemically identical to lovastatin; combined with a statin it adds toxicity. NCCIH — Red Yeast Rice
Key Studies ★ 12 studies
Umbrella review
15 meta-analyses, 186 RCTs
✓ PubMed
A 2024 umbrella review found red yeast rice was generally not associated with liver or muscular adverse events versus control, but rated the credibility of this safety evidence as low and called for higher-quality data.
Meta-analysis
Cheung 2024 (Nutrients)
✓ Full text
Pooled analysis of 14 double-blind RCTs (705 hypercholesterolemic participants) found red yeast rice extract reduced LDL-C by 35.82 mg/dL (95% CI -43.36 to -28.29) with no life-threatening or frequent side effects.
Meta-analysis of RCTs
15 RCTs, 1,012 participants
✓ PubMed
In a 2022 meta-analysis of 15 high-quality randomized trials, red yeast rice used alone lowered LDL cholesterol by a mean of 28.4 mg/dL (95% CI -37.0 to -19.8) versus control, comparable to low-dose statins.
Meta-analysis
Lu 2022 (Front Pharmacol)
✓ Full text
Meta-analysis of 15 high-quality RCTs (1,012 participants) found red yeast rice lowered LDL-C vs placebo (MD -35.82 mg/dL, 95% CI -43.36 to -28.29) and was non-inferior to statins (MD 1.89, 95% CI -7.93 to 11.71, p=0.71).
Regulatory safety opinion
EFSA scientific opinion
✓ Full text
EFSA's 2025 opinion reaffirmed it could not establish a safe intake level for monacolins from red yeast rice, concluding that exposure as low as 3 mg/day of monacolin K could cause severe musculoskeletal effects (including rhabdomyolysis) and liver injury.
Agency / regulator
EFSA NDA Panel 2025
✓ PubMed
EFSA concluded that monacolin K from red yeast rice at intakes as low as 3 mg/day could cause severe adverse effects (rhabdomyolysis, liver injury) and that no daily intake of monacolins free of safety concern could be established.
Meta-analysis
Gerards 2015
✓ PubMed
Systematic review/meta-analysis of 20 RCTs: RYR lowered LDL-C by 1.02 mmol/L (95% CI -1.20 to -0.83) vs placebo, an effect statistically indistinguishable from statins (difference 0.03 mmol/L); liver/kidney injury incidence 0-5%, not different from controls, though safety assessment quality was low.
Guideline
Banach / ILEP Position Paper 2022
✓ PubMed
International Lipid Expert Panel consensus: RYR (active monacolin K, chemically identical to lovastatin) is safe and effective for lowering LDL-C and CV events; recommended particularly in low/moderate CV-risk patients and statin-intolerant patients, with conventional drugs preferred when strongest event evidence is needed.
Regulatory safety opinion
EFSA scientific opinion (2018)
✓ Full text
EFSA's foundational 2018 opinion concluded that monacolins from red yeast rice at doses around 10 mg/day raise the same safety concerns as lovastatin and that no safe level could be identified, prompting EU regulatory restrictions.
Systematic safety review
Pharmacovigilance + meta-analyses
✓ Full text
A 2024 review of adverse-event reporting systems and meta-analyses concluded red yeast rice is unlikely to cause meaningful muscle, liver, or kidney injury at low monacolin doses, while documenting rare reports of myopathy and rhabdomyolysis in spontaneous reporting databases.
Safety / toxicology
Postmarketing nutrivigilance 2024
✓ Full text
2024 postmarketing nutrivigilance analysis of a red yeast rice dietary-supplement line for dyslipidemia reported a low rate of adverse events with no signal for serious hepatic or muscular toxicity.
RCT
Lu (CCSPS) 2008
✓ PubMed
Landmark double-blind RCT in ~5,000 Chinese post-MI patients: Xuezhikang (partially purified RYR extract) over mean 4.5 yr cut major coronary events from 10.4% to 5.7% (relative reduction 45%), reduced CV and total mortality by 30% and 33%, and lowered LDL-C and triglycerides while raising HDL-C; well tolerated.